IMNN

Imunon Inc. (IMNN) | Rumor.io

Imunon

IMNN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,510

Bullish sentiment (50-day avg)85%

Price to earnings ratio-0.2

Market capitalization7.7M

Earnings per share-2.92

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-14.5M

Social

What share of all stock conversation is about IMNN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% -0.01

Sep 10

Imunon, Inc. (IMNN) has entered a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to advance the clinical development of IMNN-001.
The agreement aims to expand IMNN-001 clinical development into new tumor types while preserving key intellectual property rights for Imunon.
The partnership is expected to accelerate data generation for IMNN-001 and validate the IL-12 DNA plasmid vector's efficacy, with potential benefits for investors.

Generated by AI

Sentiment

Of the messages about IMNN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50%	81.82% -18.18	85.71% +4.76	87.55% +8.87
Bearish	50%	18.18% +18.18	14.29% -4.76	12.45% -8.87

Bullish· Jul 30

*IMNN* is expected to bounce off lows and potentially experience a price jump due to its upward trend and break of the lower Bollinger Band.
The company's recent dosing of the first patient in its pivotal Phase 3 trial for advanced ovarian cancer has set up a potentially strong continuation into earnings on August 5.
*IMNN* is considered undervalued, with a potential market capitalization of $150-200 million currently and $1-2 billion at the end of Phase 3, making it a potentially lucrative investment opportunity.

Bearish· Jul 30

The company's stock price has been heavily diluted, with multiple reverse splits and a potential cash raise, which may be a sign of financial distress.
The company's management has been accused of engaging in pump-and-dump schemes, using fake news and hype to artificially inflate the stock price before selling it off to unsuspecting investors.
The company's recent Phase 3 dosing announcement for ovarian cancer has been dismissed as a "lame catalyst" and a "big nothing burger," suggesting that the news may not be as significant as the company claims.

Generated by AI

Topics

Of the messages about IMNN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	87.97%
Earnings	—	0%	0%	2.07%
Technical Analysis	—	0%	0%	9.96%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· May 23

Imunon, Inc. (IMNN) announced new positive data from the Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer.
The company will present the data in an oral presentation at the 2025 ASCO Annual Meeting and will publish the results simultaneously in the peer-reviewed journal Gynecologic Oncology.
The Phase 2 trial results indicate that IMNN-001 could extend the lives of women with newly diagnosed advanced ovarian cancer by one year or longer, representing a potentially historic advance in standard of care.

Technical Analysis· Jun 2

$IMNN is expected to continue its upward trend, with a possible range to $3.3 or $3.6.
The stock is showing a strong cup and handle move on the daily chart, indicating a potential breakout.
The 1H chart for $IMNN remains intact, with support levels at $2.50, $2.30, $1.90, and $1.30.

Generated by AI

Community

Of the messages about IMNN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	76.79%	64.04%	75.22%
Newcomers	33.33%	23.21%	35.96%	24.78%

Regulars· Jul 21

The company's lead drug, IMNN-001, continues to show promise in advanced ovarian cancer patients, with a recent phase 2 trial demonstrating a successful overcoming of historical IL-12 safety barriers.
A new phase 2 trial is underway, this time at MD Anderson and other tier 1 research hospitals, which may lead to the initiation of a phase 3 trial, given the prestige of these sites.
The company's market capitalization is currently $8 million, but the regulars believe it has the potential to grow into a multi-billion dollar market cap, given its promising cancer treatment and significant market size (20,000 women/year in the US and 90,000/year worldwide).

Newcomers· Jul 21

Newcomers are focused on the positive Phase 2 MRD data showing lower residual disease and higher ctDNA clearance for Imunon's IL-12 therapy.
Many are confused by the high volume and price movement, but the price has actually reached new lows.
Some newcomers are attributing the high volume to short action, with the ticker movement suggesting that the company may not be responsible for the sell-off.

Generated by AI

News

Imunon exchanges $1.2M debt for preferred stock

23h agoInvesting.com

Imunon, Inc. (IMNN) Shareholder/Analyst Call - Slideshow (NASDAQ:IMNN) 2026-09-24

2026-09-24. The following slide deck was published by Imunon, Inc.

5d agoSeeking Alpha

Imunon presents Phase 2 ovarian cancer survival data at R&D day

5d agoInvesting.com

IMUNON’s ovarian cancer study continues after safety review

7d agoInvesting.com

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date, reinforcing IMNN-001's differentiated safety profile as an IL-12-based immunotherapy MRD study has now demonstrated the safety and tolerability of IMNN-001 both in combination with bevacizumab and in the maintenance setting Recommenda

7d agoYahoo! Finance Canada

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration LAWRENCEVILLE, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced it has entered into a Cooperative Research and Development

19d agoYahoo Finance

Also Discussed

Investors talking about IMNN also mention

#	Name	Attention
1	GMAN - Goldman Sachs Manufacturing Revolution ETF	——
2	Global X Genomics & Biotechnology ETFGNOM	0.01%+0
3	VistaShares Artificial Intelligence Supercycle ETFAIS	0%0
4	Opus Genetics Inc.OCUP	0%0
5	CDMO - Avid Bioservices, Inc.	——
6	Delcath Systems, Inc.DCTH	0%new
7	NAVB - Navidea Biopharmaceuticals, Inc.	——
8	ANAC - Arctos NorthStar Acquisition Corp.	——
9	ATXS - Astria Therapeutics, Inc.	——
10	Phio Pharmaceuticals Corp.PHIO	0%new

Imunon Inc.

Healthcare
Biotechnology

Imunon Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines for difficult-to-treat diseases. The company’s current portfolio centers on proprietary non-viral DNA platforms designed to activate the body’s immune system at the site of disease, with applications in oncology and infectious diseases. Its lead program, IMNN-001, is being developed as a localized immunotherapy for advanced ovarian cancer, while its PlaCCine platform supports nucleic acid vaccine research for infectious disease targets. Imunon also advances additional preclinical and early-stage programs across solid tumors and viral indications. Headquartered in Lawrenceville, New Jersey, Imunon plays a specialized role in the biotechnology market by pursuing platform-based treatments that combine immunology, gene delivery, and cancer therapy research.

Website

Location

997 Lenox Drive

Lawrenceville, NJ, 08648

United States

Social

What share of all stock conversation is about IMNN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% -0.01

Sep 10

Imunon, Inc. (IMNN) has entered a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to advance the clinical development of IMNN-001.
The agreement aims to expand IMNN-001 clinical development into new tumor types while preserving key intellectual property rights for Imunon.
The partnership is expected to accelerate data generation for IMNN-001 and validate the IL-12 DNA plasmid vector's efficacy, with potential benefits for investors.

Generated by AI

Sentiment

Of the messages about IMNN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50%	81.82% -18.18	85.71% +4.76	87.55% +8.87
Bearish	50%	18.18% +18.18	14.29% -4.76	12.45% -8.87

Bullish· Jul 30

*IMNN* is expected to bounce off lows and potentially experience a price jump due to its upward trend and break of the lower Bollinger Band.
The company's recent dosing of the first patient in its pivotal Phase 3 trial for advanced ovarian cancer has set up a potentially strong continuation into earnings on August 5.
*IMNN* is considered undervalued, with a potential market capitalization of $150-200 million currently and $1-2 billion at the end of Phase 3, making it a potentially lucrative investment opportunity.

Bearish· Jul 30

The company's stock price has been heavily diluted, with multiple reverse splits and a potential cash raise, which may be a sign of financial distress.
The company's management has been accused of engaging in pump-and-dump schemes, using fake news and hype to artificially inflate the stock price before selling it off to unsuspecting investors.
The company's recent Phase 3 dosing announcement for ovarian cancer has been dismissed as a "lame catalyst" and a "big nothing burger," suggesting that the news may not be as significant as the company claims.

Generated by AI

Topics

Of the messages about IMNN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	87.97%
Earnings	—	0%	0%	2.07%
Technical Analysis	—	0%	0%	9.96%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· May 23

Imunon, Inc. (IMNN) announced new positive data from the Phase 2 OVATION 2 Study of IMNN-001, an investigational therapy for the treatment of advanced ovarian cancer.
The company will present the data in an oral presentation at the 2025 ASCO Annual Meeting and will publish the results simultaneously in the peer-reviewed journal Gynecologic Oncology.
The Phase 2 trial results indicate that IMNN-001 could extend the lives of women with newly diagnosed advanced ovarian cancer by one year or longer, representing a potentially historic advance in standard of care.

Technical Analysis· Jun 2

$IMNN is expected to continue its upward trend, with a possible range to $3.3 or $3.6.
The stock is showing a strong cup and handle move on the daily chart, indicating a potential breakout.
The 1H chart for $IMNN remains intact, with support levels at $2.50, $2.30, $1.90, and $1.30.

Generated by AI

Community

Of the messages about IMNN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	66.67%	76.79%	64.04%	75.22%
Newcomers	33.33%	23.21%	35.96%	24.78%

Regulars· Jul 21

The company's lead drug, IMNN-001, continues to show promise in advanced ovarian cancer patients, with a recent phase 2 trial demonstrating a successful overcoming of historical IL-12 safety barriers.
A new phase 2 trial is underway, this time at MD Anderson and other tier 1 research hospitals, which may lead to the initiation of a phase 3 trial, given the prestige of these sites.
The company's market capitalization is currently $8 million, but the regulars believe it has the potential to grow into a multi-billion dollar market cap, given its promising cancer treatment and significant market size (20,000 women/year in the US and 90,000/year worldwide).

Newcomers· Jul 21

Newcomers are focused on the positive Phase 2 MRD data showing lower residual disease and higher ctDNA clearance for Imunon's IL-12 therapy.
Many are confused by the high volume and price movement, but the price has actually reached new lows.
Some newcomers are attributing the high volume to short action, with the ticker movement suggesting that the company may not be responsible for the sell-off.

Generated by AI

Imunon

Social

Sep 10

Bullish· Jul 30

Bearish· Jul 30

Announcements· May 23

Technical Analysis· Jun 2

Regulars· Jul 21

Newcomers· Jul 21

Imunon exchanges $1.2M debt for preferred stock

Imunon, Inc. (IMNN) Shareholder/Analyst Call - Slideshow (NASDAQ:IMNN) 2026-09-24

Imunon presents Phase 2 ovarian cancer survival data at R&D day

IMUNON’s ovarian cancer study continues after safety review

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

Also Discussed

Imunon Inc.

Company Information

Location

Imunon exchanges $1.2M debt for preferred stock

Imunon, Inc. (IMNN) Shareholder/Analyst Call - Slideshow (NASDAQ:IMNN) 2026-09-24

Imunon presents Phase 2 ovarian cancer survival data at R&D day

IMUNON’s ovarian cancer study continues after safety review

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

Also Discussed

Social

Sep 10

Bullish· Jul 30

Bearish· Jul 30

Announcements· May 23

Technical Analysis· Jun 2

Regulars· Jul 21

Newcomers· Jul 21